BIO-TECHNE Corp (TECH) reported quarterly earnings results on Tuesday, May-3-2016. The company said it had a profit of $1.01 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.12. Analysts had a consensus of $0.89. The company posted revenue of $130.97 million in the period, compared to analysts expectations of $122.71 million. The company’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 EPS.
BIO-TECHNE Corp opened for trading at $93.11 and hit $94.68 on the upside on Monday, eventually ending the session at $93.3, with a gain of 0.13% or 0.12 points. The heightened volatility saw the trading volume jump to 2,10,486 shares. Company has a market cap of $3,470 M.
In a different news, on Apr 22, 2016, Roger C Lucas (director) sold 100 shares at $92.40 per share price. According to the SEC, on Jun 9, 2015, Randolph C Steer (director) sold 1,000 shares at $99.39 per share price. On Feb 20, 2015, Howard V Oconnell (director) sold 5,000 shares at $95.78 per share price, according to the Form-4 filing with the securities and exchange commission.
Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.